<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01525667</url>
  </required_header>
  <id_info>
    <org_study_id>PLX-PAD 1301-01</org_study_id>
    <nct_id>NCT01525667</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IM Injections of PLX-PAD for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty</brief_title>
  <official_title>A Phase I/II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pluristem Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pluristem Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Local administration of PLX-PAD single dose, intra-muscular injection for the regeneration of
      injured gluteal musculature after Total Hip Arthroplasty (THA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the main problems when performing THA via the standard transgluteal approach is the
      necessary injury of the gluteus medius muscle. The consecutive decrease of contractile muscle
      substance and the substitution by scar tissue leads to functional deficits of the
      pelvic-stabilizing musculature with an insufficiency limp in a large number of patients. In
      the long run the lack of musculature leads to a decrease in bone substance at the insertion
      sites of the gluteal muscles of the proximal femur. The present study has the aim of
      establishing a new therapy for iatrogenic gluteal muscle damage. The hypothesis of the
      present proposal is that intra-muscular (IM) injection of PLX-PAD into the iatrogenically
      injured gluteus medius muscle after THA results in an improved regeneration of the skeletal
      muscle tissue and consecutively in an improved functional outcome.

      Subjects will be assigned to receive one of the two targeted doses of PLX-PAD or placebo. On
      the treatment day, after suturing the gluteus medius muscle PLX-PAD or placebo will be
      applied directly to the site of laceration.

      Patients will be followed up for efficacy assessment up to week 26 and for safety assessment
      (Adverse events, vital signs, ECG, routinf lab and immunological testing) up to week 52 after
      THA. Patients will be phoned at week 104 in order to inquire about the occurence of new
      cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Day 0 to Week 26 in the Maximal Voluntary Isometric Contraction (MVIC) Moment of the Injured Side to Assess Gluteus Medius Strength.</measure>
    <time_frame>Day 0 to Week 26</time_frame>
    <description>Change from Visit 2 (Day 0) to Week 26 in the maximal voluntary isometric contraction (MVIC) moment of the injured side as measured by isometric dynamometry to assess Gluteus Medius force strength.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Day 0 to Week 26 in Muscle Volume.</measure>
    <time_frame>Day 0 to Week 26</time_frame>
    <description>Change from Visit 2 (Day 0) to Week 26 in Muscle Volume as Measured by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Day 1 to Week 12 in Mean Fiber Diameter.</measure>
    <time_frame>Day 1 to Week 12</time_frame>
    <description>Change from Visit 3 (Day 1) to Week 12 in Mean Fiber Diameter as Measured by Muscle Biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Day 0 to Week 26 in the Ratio of Injured to Contralateral Pelvic Shift .</measure>
    <time_frame>Day 0 to Week 26</time_frame>
    <description>Change from Visit 2 (Day 0) to Week 26 in the Ratio of Injured to Contralateral Pelvic Shift as Measured by Gait Analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Day 0 to Week 26 in the Visual Analog Scale (VAS) Pain Score.</measure>
    <time_frame>Day 0 to Week 26</time_frame>
    <description>Visual Analog Scale (VAS) Pain Score ranges from 0 mm (no pain) to 100 mm (worse possible pain)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Total Hip Arthroplasty</condition>
  <condition>Muscle Injury</condition>
  <arm_group>
    <arm_group_label>150M PLX-PAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single course, multiple IM injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300M PLX-PAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single course, multiple IM injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single course, multiple IM injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>150M PLX-PAD</intervention_name>
    <description>Single course, multiple IM injections</description>
    <arm_group_label>150M PLX-PAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>300M PLX-PAD</intervention_name>
    <description>Single course, multiple IM injections</description>
    <arm_group_label>300M PLX-PAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single course, multiple IM injections</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects between 50 to 75 years of age

          2. Scheduled THA

          3. ASA Score ≤ 3

          4. Signed written informed consent

        Exclusion Criteria:

          1. Muscle diseases

          2. Severe neurological diseases

          3. Opioid long term medication

          4. Pain chronification &gt; stadium II of Gerbershagen

          5. Immunosuppression due to illness or medication

          6. Ankylosing spondylitis

          7. History of ectopic bone formation of any localisation

          8. Exclusion criteria for MRI (pace maker, defibrillator, ferromagnetic intracerebral
             clips)

          9. Uncontrolled hypertension (defined as diastolic blood pressure &gt; 100 mmHg or systolic
             blood pressure &gt; 200 mmHg during screening)

         10. Life-threatening ventricular arrhythmia or unstable angina - characterized by
             increasingly frequent episodes with modest exertion or at rest, worsening severity,
             and prolonged

         11. ST segment elevation myocardial infarction and/or TIA/CVA within three (3) months
             prior to enrollment. Subjects with severe congestive heart failure symptoms (i.e. NYHA
             Stage IV)

         12. Subject has malignancy undergoing treatment including chemotherapy, radiotherapy or
             immunotherapy

         13. Body Mass Index (BMI) of 35 Kg/m2 or greater

         14. Known allergies to protein products (horse or bovine serum, or porcine trypsin) used
             in the cell production process

         15. Known HIV, syphilis at time of screening

         16. Known active Hepatitis B, or Hepatitis C infection at the time of screening

         17. Pregnant or breast-feeding women or women of childbearing potential not protected by
             an effective contraceptive method of birth control (defined as pearl index &lt; 1)

         18. In the opinion of the investigator, the subject is unsuitable for cellular therapy

         19. Subject is currently enrolled in, or has not yet completed a period of at least 30
             days since ending other investigational device or drug trial(s)

         20. Subjects who are legally detained in an official institute
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carsten Perka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité Universitätsmedizin Berlin, Dept. Of Orthopedic Surgery, Charitéplatz 1, 10117 Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2012</study_first_submitted>
  <study_first_submitted_qc>February 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2012</study_first_posted>
  <results_first_submitted>January 1, 2015</results_first_submitted>
  <results_first_submitted_qc>February 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2015</results_first_posted>
  <last_update_submitted>September 7, 2015</last_update_submitted>
  <last_update_submitted_qc>September 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>THA</keyword>
  <keyword>Muscle injury</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PLX-PAD Low Dose</title>
          <description>150M PLX-PAD : Single treatment, multiple injections</description>
        </group>
        <group group_id="P2">
          <title>PLX-PAD High Dose</title>
          <description>300M PLX-PAD : Single treatment, multiple injections</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo: Single treatment, multiple injections</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PLX-PAD Low Dose</title>
          <description>PLX-PAD low dose: Single treatment, multiple injections</description>
        </group>
        <group group_id="B2">
          <title>PLX-PAD High Dose</title>
          <description>PLX-PAD high dose: Single treatment, multiple injections</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo: Single treatment, multiple injections</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.4" spread="5.9"/>
                    <measurement group_id="B2" value="64.5" spread="7.4"/>
                    <measurement group_id="B3" value="64.3" spread="6.4"/>
                    <measurement group_id="B4" value="64.8" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Day 0 to Week 26 in the Maximal Voluntary Isometric Contraction (MVIC) Moment of the Injured Side to Assess Gluteus Medius Strength.</title>
        <description>Change from Visit 2 (Day 0) to Week 26 in the maximal voluntary isometric contraction (MVIC) moment of the injured side as measured by isometric dynamometry to assess Gluteus Medius force strength.</description>
        <time_frame>Day 0 to Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PLX-PAD Low Dose</title>
            <description>PLX-PAD low dose: Single treatment, multiple injections</description>
          </group>
          <group group_id="O2">
            <title>PLX-PAD High Dose</title>
            <description>PLX-PAD high dose: Single treatment, multiple injections</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Single treatment, multiple injections</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Day 0 to Week 26 in the Maximal Voluntary Isometric Contraction (MVIC) Moment of the Injured Side to Assess Gluteus Medius Strength.</title>
          <description>Change from Visit 2 (Day 0) to Week 26 in the maximal voluntary isometric contraction (MVIC) moment of the injured side as measured by isometric dynamometry to assess Gluteus Medius force strength.</description>
          <units>Newtons</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.17" spread="6.97"/>
                    <measurement group_id="O2" value="20.36" spread="7.61"/>
                    <measurement group_id="O3" value="5.43" spread="6.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0067</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Least Square Means (LSM) Difference</param_type>
            <param_value>25.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.94</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.61</ci_lower_limit>
            <ci_upper_limit>43.86</ci_upper_limit>
            <estimate_desc>LSM difference =LSM Low dose - LSM Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Least Square Means (LSM) difference</param_type>
            <param_value>14.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.12</ci_lower_limit>
            <ci_upper_limit>36.99</ci_upper_limit>
            <estimate_desc>LSM difference= LSM High Dose - LSM Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Day 0 to Week 26 in Muscle Volume.</title>
        <description>Change from Visit 2 (Day 0) to Week 26 in Muscle Volume as Measured by MRI.</description>
        <time_frame>Day 0 to Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150M PLX-PAD</title>
            <description>PLX-PAD low dose: Single treatment, multiple injections</description>
          </group>
          <group group_id="O2">
            <title>300M PLX-PAD</title>
            <description>PLX-PAD high dose: Single treatment, multiple injections</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Single treatment, multiple injections</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Day 0 to Week 26 in Muscle Volume.</title>
          <description>Change from Visit 2 (Day 0) to Week 26 in Muscle Volume as Measured by MRI.</description>
          <units>mm3</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.42" spread="4.18"/>
                    <measurement group_id="O2" value="15.62" spread="4.91"/>
                    <measurement group_id="O3" value="6.39" spread="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>18.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.03</ci_lower_limit>
            <ci_upper_limit>30.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM difference</param_type>
            <param_value>9.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.72</ci_lower_limit>
            <ci_upper_limit>23.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Day 1 to Week 12 in Mean Fiber Diameter.</title>
        <description>Change from Visit 3 (Day 1) to Week 12 in Mean Fiber Diameter as Measured by Muscle Biopsy.</description>
        <time_frame>Day 1 to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150M PLX-PAD</title>
            <description>PLX-PAD low dose: Single treatment, multiple injections</description>
          </group>
          <group group_id="O2">
            <title>300M PLX-PAD</title>
            <description>PLX-PAD high dose: Single treatment, multiple injections</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Single treatment, multiple injections</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Day 1 to Week 12 in Mean Fiber Diameter.</title>
          <description>Change from Visit 3 (Day 1) to Week 12 in Mean Fiber Diameter as Measured by Muscle Biopsy.</description>
          <units>microns</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="3.27"/>
                    <measurement group_id="O2" value="0.28" spread="3.23"/>
                    <measurement group_id="O3" value="-5.21" spread="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>ANCOVA</method>
            <param_type>LSM Difference</param_type>
            <param_value>6.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.50</ci_lower_limit>
            <ci_upper_limit>16.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>ANCOVA</method>
            <param_type>LSM difference</param_type>
            <param_value>5.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.29</ci_lower_limit>
            <ci_upper_limit>15.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Day 0 to Week 26 in the Ratio of Injured to Contralateral Pelvic Shift .</title>
        <description>Change from Visit 2 (Day 0) to Week 26 in the Ratio of Injured to Contralateral Pelvic Shift as Measured by Gait Analysis</description>
        <time_frame>Day 0 to Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150M PLX-PAD</title>
            <description>PLX-PAD low dose: Single treatment, multiple injections</description>
          </group>
          <group group_id="O2">
            <title>300M PLX-PAD</title>
            <description>PLX-PAD high dose: Single treatment, multiple injections</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Single treatment, multiple injections</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Day 0 to Week 26 in the Ratio of Injured to Contralateral Pelvic Shift .</title>
          <description>Change from Visit 2 (Day 0) to Week 26 in the Ratio of Injured to Contralateral Pelvic Shift as Measured by Gait Analysis</description>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.13"/>
                    <measurement group_id="O2" value="0.28" spread="0.14"/>
                    <measurement group_id="O3" value="0.27" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.011</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Day 0 to Week 26 in the Visual Analog Scale (VAS) Pain Score.</title>
        <description>Visual Analog Scale (VAS) Pain Score ranges from 0 mm (no pain) to 100 mm (worse possible pain)</description>
        <time_frame>Day 0 to Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150M PLX-PAD</title>
            <description>PLX-PAD low dose: Single treatment, multiple injections</description>
          </group>
          <group group_id="O2">
            <title>300M PLX-PAD</title>
            <description>PLX-PAD high dose: Single treatment, multiple injections</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Single treatment, multiple injections</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Day 0 to Week 26 in the Visual Analog Scale (VAS) Pain Score.</title>
          <description>Visual Analog Scale (VAS) Pain Score ranges from 0 mm (no pain) to 100 mm (worse possible pain)</description>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.76" spread="5.90"/>
                    <measurement group_id="O2" value="-37.87" spread="6.53"/>
                    <measurement group_id="O3" value="-48.57" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM difference</param_type>
            <param_value>16.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>33.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM difference</param_type>
            <param_value>10.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.26</ci_lower_limit>
            <ci_upper_limit>28.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data were collected for total period of 1 year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>150M PLX-PAD</title>
          <description>PLX-PAD low dose: Single treatment, multiple injections</description>
        </group>
        <group group_id="E2">
          <title>300M PLX-PAD</title>
          <description>PLX-PAD high dose: Single treatment, multiple injections</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo: Single treatment, multiple injections</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>HUMERAL HEAD FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>PERIURETHRAL CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Post procedural swelling</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Suture related complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Breath odour</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Esther Lukasiewicz Hagai</name_or_title>
      <organization>Pluristem Ltd.</organization>
      <phone>+972-972-74-710-8600 ext 694</phone>
      <email>estherl@Pluristem.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

